Klingman & Associates LLC Acquires 254 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 2nd, 2023

Klingman & Associates LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,515 shares of the company’s stock after purchasing an additional 254 shares during the quarter. Klingman & Associates LLC’s holdings in Johnson & Johnson were worth $3,094,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Nordwand Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $785,273,000. Edmp Inc. boosted its position in shares of Johnson & Johnson by 17,222.9% during the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock valued at $18,247,000 after buying an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. GQG Partners LLC boosted its position in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.1 %

Shares of Johnson & Johnson stock opened at $163.60 on Tuesday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $183.35. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock has a market cap of $426.06 billion, a PE ratio of 34.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The company has a 50-day moving average of $157.86 and a two-hundred day moving average of $167.04.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same quarter last year, the business earned $2.67 earnings per share. Johnson & Johnson’s revenue was up 5.6% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.91%. Johnson & Johnson’s payout ratio is 94.56%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on JNJ shares. Raymond James decreased their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. UBS Group initiated coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Finally, SVB Leerink decreased their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.